Monograph
V08CA03 - Gadodiamide |
Not porphyrinogenic |
NP |
Rationale
Gadodiamide is excreted unchanged though the kidneys.
Chemical description
Gadodiamide is a nonionic gadolinium chelate.
Therapeutic characteristics
Gadodiamide is used as a magnetic resonance contrast medium. It is administered intravenously. Nausea is a common adverse reaction of gadodiamide that can be confused with an acute porphyric attack.
Hepatic exposure
Not relevant.
Metabolism and pharmacokinetics
Gadodiamide is rapidly distributed into extracellular fluid. About 96% of a dose is excreted unchanged in the urine within 24 hours. No metabolites have been found.
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | Sweetman SC, editor. Martindale: The complete drug reference. Gadodiamide. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Omniscan.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Latvia© NAPOS 2024